The direct-acting antiviral glecaprevir/pibrentasvir (Mavyret) was highly effective and well tolerated in adults with acute ...

Mavyret is intended to treat adults with all types of chronic hepatitis C virus with mild or no cirrhosis who have not previously received treatment for the illness. Patients with moderate to severe ...

ALL CLEAR: “I don't have to worry about [hepatitis C] anymore or worry about it progressively getting worse,” says Maia Hughes, who sought treatment for HCV in 2018. She cleared the virus from her ...

HCV—can persist in the livers of those infected and even lead to liver disease or failure in extreme cases. It affects tens ...

The Food and Drug Administration granted breakthrough therapy designation to a treatment regimen of two investigational drugs for patients with chronic hepatitis C virus who did not respond to ...

Dr. Céline Gounder, an internist, epidemiologist and infectious disease specialist, is a CBS News medical contributor as well as senior fellow and editor-at-large for public health at KFF Health News.

U ntil recently, most people diagnosed with hepatitis C were baby boomers, many of whom got the infection via a blood transfusion. As of 2024, hepatitis C is mostly spread via needles, syringes, and ...

New medications called direct-acting antivirals (DAAs) have transformed the treatment of hepatitis C. Twelve weeks on one of these drugs cures the infection in 95 percent or more of people who take it ...

These pills are easy-to-take oral antivirals with few side effects. They cure 95% of patients who take them. The treatments are also expensive, coming in at $20 to 25,000 dollars a course. A new ...